Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.

MLA

Maksymowych, Walter P., et al. “Modification of Structural Lesions on MRI of the Sacroiliac Joints by Etanercept in the EMBARK Trial: A 12-Week Randomised Placebo-Controlled Trial in Patients with Non-Radiographic Axial Spondyloarthritis.” Annals of the Rheumatic Diseases, vol. 77, no. 1, Jan. 2018, pp. 78–84. EBSCOhost, https://doi.org/10.1136/annrheumdis-2017-211605.

APA

Maksymowych, W. P., Wichuk, S., Dougados, M., Jones, H. E., Pedersen, R., Szumski, A., Marshall, L., Bukowski, J. F., & Lambert, R. G. (2018). Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis. Annals of the Rheumatic Diseases, 77(1), 78–84. https://doi.org/10.1136/annrheumdis-2017-211605

Chicago

Maksymowych, Walter P., Stephanie Wichuk, Maxime Dougados, Heather E. Jones, Ron Pedersen, Annette Szumski, Lisa Marshall, Jack F. Bukowski, and Robert G. Lambert. 2018. “Modification of Structural Lesions on MRI of the Sacroiliac Joints by Etanercept in the EMBARK Trial: A 12-Week Randomised Placebo-Controlled Trial in Patients with Non-Radiographic Axial Spondyloarthritis.” Annals of the Rheumatic Diseases 77 (1): 78–84. doi:10.1136/annrheumdis-2017-211605.